ADHDNCT07380412
A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications
A study testing Stasis Daytime and Nighttime in people with ADHD and Sleep Disturbance, run by Outliers, Inc. at 1 site in United States.
Trial summary
This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant medications used for ADHD over a three-month period in adults. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- ADHD, Sleep Disturbance, Brain Fog
- What is being tested?
- Stasis Daytime and Nighttime
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Aug 2025to Mar 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Aged 18-55 years
- Currently prescribed stimulant medication for ADHD
- Experiencing: sleep difficulty, irritability, anxiety, brain fog
- Stable medication dose ≥3 months
- Healthy with no uncontrolled chronic conditions
- Stable on supplements ≥3 months if applicable
- US resident
- Willing to maintain current habits
Who cannot join
- Chronic conditions (e.g. cancer, mental illness)
- Use of psychiatric medications besides stimulants
- Pregnancy, breastfeeding, thyroid, liver, kidney conditions
- Recent smokers or heavy alcohol use
- Night shift workers
- Participation in other clinical trials
- Allergies to product ingredients
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Citruslabs
Las Vegas, Nevada, 89118
Patrick Renner, MSc, 424-245-0284, hello@citruslabs.com
About this study
This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant medications used for ADHD over a three-month period in adults.
- Conditions
- ADHD, Sleep Disturbance, Brain Fog
- Being tested
- Stasis Daytime and Nighttime, Placebo
- Keywords
- ADHD, Anxiety
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity, Parasomnias, Mental Fatigue, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Stasis Daytime and NighttimeDietary supplement
Daytime taken with stimulant medication and food. Nighttime taken 30 minutes before bedtime on an empty stomach.
PlaceboDietary supplement
Matched placebo product in taste and appearance.
| Study group | Role | What they receive |
|---|---|---|
| Stasis Supplement | Experimental | Not described Receives: Dietary Supplement: Stasis Daytime and Nighttime |
| Placebo Comparator | Placebo comparator | Not described Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in oxidative stress and cortisol levels as measured by hs-CRP, 8-OHdG
Measurement of oxidative stress and cortisol levels will be assessed using the following validated biomarkers:
hs-CRP and serum cortisol from blood samples 8-hydroxy-2'-deoxyguanosine (8-OHdG) from urine samples
Measured: Baseline and Month 3
Change in cortisol levels
Serum cortisol concentration measured via blood draw.
Measured: Baseline and Month 3
Secondary outcomes (9)
Change in sleep quality
Sleep quality assessed via self-report questionnaire.
Measured: Baseline, Month 1, Month 2, and Month 3
Change in irritability
Irritability assessed via self-report questionnaire.
Measured: Baseline, Month 1, Month 2, and Month 3
Change in focus
Focus assessed via self-report questionnaire.
Measured: Baseline, Month 1, Month 2, and Month 3
Change in sociability
Sociability assessed via self-report questionnaire.
Measured: Baseline, Month 1, Month 2, and Month 3
Change in self-reported mood
Mood assessed via self-report questionnaire.
Measured: Baseline, Month 1, Month 2, and Month 3
Change in self-reported stress
Stress levels assessed via self-report questionnaire.
Measured: Baseline, Month 1, Month 2, and Month 3
Change in self-reported appetite
Appetite assessed via self-report questionnaire.
Measured: Baseline, Month 1, Month 2, and Month 3
Change in blood levels of Vitamin C
Serum levels of Vitamin C measured via blood test.
Measured: Baseline and Month 3
Change in blood levels of CoQ10
Serum levels of Coenzyme Q10 measured via blood test.
Measured: Baseline and Month 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Feb 2026
- Study start12 Aug 2025
- Primary completionMar 2026 (estimated)
- Study completionMar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ADHDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Outliers, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07380412
- Sponsor's protocol ID
- 20764
- Status last verified
- Jan 2026
- First submitted
- 27 Nov 2025
- Last updated
- 2 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications
- ClinicalTrials.gov ID
- NCT07380412
- Acronym / sponsor ID
- 20764
- Conditions
- ADHD, Sleep Disturbance, Brain Fog
- Keywords
- ADHD, Anxiety
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Outliers, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 12 Aug 2025 (actual)
- Primary completion
- Mar 2026 (estimated)
- Study completion
- Mar 2026 (estimated)
- First posted
- 2 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant medications used for ADHD over a three-month period in adults.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Stasis Supplement | Experimental | Dietary Supplement: Stasis Daytime and Nighttime |
| Placebo Comparator | Placebo comparator | Dietary Supplement: Placebo |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Aged 18-55 years
- Currently prescribed stimulant medication for ADHD
- Experiencing: sleep difficulty, irritability, anxiety, brain fog
- Stable medication dose ≥3 months
- Healthy with no uncontrolled chronic conditions
Key exclusion criteria (7 listed)
- Chronic conditions (e.g. cancer, mental illness)
- Use of psychiatric medications besides stimulants
- Pregnancy, breastfeeding, thyroid, liver, kidney conditions
- Recent smokers or heavy alcohol use
- Night shift workers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Stasis Daytime and NighttimeDaytime taken with stimulant medication and food. Nighttime taken 30 minutes before bedtime on an empty stomach. | Dietary supplement | Stasis Supplement |
| PlaceboMatched placebo product in taste and appearance. | Dietary supplement | Placebo Comparator |
Primary outcome
Change in oxidative stress and cortisol levels as measured by hs-CRP, 8-OHdG
Time frame: Baseline and Month 3
Measurement of oxidative stress and cortisol levels will be assessed using the following validated biomarkers: hs-CRP and serum cortisol from blood samples 8-hydroxy-2'-deoxyguanosine (8-OHdG) from urine samples
Change in cortisol levels
Time frame: Baseline and Month 3
Serum cortisol concentration measured via blood draw.
9 secondary outcomes
Change in sleep quality
Time frame: Baseline, Month 1, Month 2, and Month 3
Change in irritability
Time frame: Baseline, Month 1, Month 2, and Month 3
Change in focus
Time frame: Baseline, Month 1, Month 2, and Month 3
Change in sociability
Time frame: Baseline, Month 1, Month 2, and Month 3
Change in self-reported mood
Time frame: Baseline, Month 1, Month 2, and Month 3
Change in self-reported stress
Time frame: Baseline, Month 1, Month 2, and Month 3
Change in self-reported appetite
Time frame: Baseline, Month 1, Month 2, and Month 3
Change in blood levels of Vitamin C
Time frame: Baseline and Month 3
Change in blood levels of CoQ10
Time frame: Baseline and Month 3
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2026.
Related trials for ADHD
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
Not yet recruiting
Cognitive-Motor Training With the DextEgg in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting
Virtual Reality in Rehabilitation of Executive Functions in Children With Attention Deficit Hyperactivity Disorder.
Attention Deficit Hyperactivity Disorder
RecruitingObservational study
Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy
Irritability, Disruptive Mood Dysregulation Disorder
RecruitingObservational study
Lemborexant vs Clonidine vs Sedatives to Treat Insomnia in Chronic Pain Patients
Chronic Insomnia, Chronic Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Stasis Daytime and Nighttime in people with ADHD and Sleep Disturbance, run by Outliers, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Patrick Renner, MSc (4242450284, hello@citruslabs.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in oxidative stress and cortisol levels as measured by hs-CRP, 8-OHdG (time frame: Baseline and Month 3). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2026.